Analysis of olaparib-induced hyperglycemia during three-month therapy with consideration of BMI of ovarian cancer patients

Analysis of olaparib-induced hyperglycemia during three-month therapy with consideration of BMI of ovarian cancer patients | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Analysis of olaparib-induced hyperglycemia during three-month therapy with consideration of BMI of ovarian cancer patients Joanna Stanisławiak-Rudowicz, Edyta Szałek, Barbara Więckowska, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4541315/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 29 Jan, 2025 Read the published version in Pharmacological Reports → Version 1 posted 12 You are reading this latest preprint version Abstract Introduction. Olaparib is a relatively new poly(ADP-ribose) polymerase inhibitor administered to patients with ovarian cancer (OC) with a complete or partial response to first-line chemotherapy. One of the metabolic side effects of olaparib is disruption of glucose homeostasis, resulting in hyperglycemia Aim. The aim of the study was the retrospective analysis of olaparib-induced hyperglycemia in OC patients with initial normoglycemia following I, II, and III cycle of olaparib treatment. Methods . The study involved 32 OC patients, divided into three groups according to their BMI: normal BMI (BMI 18.5-24.9 kg/m 2 ; n=13), overweight (BMI 25-29.9 kg/m 2 ; n=13), and obesity (BMI ≥30 kg/m 2 ; n=6). The fasting glucose (FG) levels were evaluated after I, II, and III cycle of olaparib treatment (a cycle means 28 days of olaparib treatment). The severity of observed hyperglycemia was assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Results. In the group with normal BMI, the increase of glycemia was statistically significant after I (p=0.0032) and II (p=0.0195) cycle of olaparib treatment, in the group with overweight – after III (p=0.0375) cycle, and in the group with obesity – after III cycle (p=0.0152). There were no statistically significant differences in glucose levels among the groups following I (p=0.7741), II (p=0.9418) and III cycle (p=0.3431). During olaparib treatment, grade 1 hyperglycemia with impaired fasting glucose levels (5.6–6.9 mmol/l) was found in 15 patients ( normal BMI: n=4, overweight n=9, and obesity n=2). Glycemia typical of diabetes (≥7.0 mmol/l) was observed in 1 obese patients. Conclusions. Regardless of the weight of OC patients, glycemic control in the course of olaparib treatment is indicated. olaparib hyperglycemia BMI adverse effects Full Text Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 29 Jan, 2025 Read the published version in Pharmacological Reports → Version 1 posted Editorial decision: Revision requested 12 Sep, 2024 Reviews received at journal 06 Sep, 2024 Reviewers agreed at journal 26 Aug, 2024 Reviewers agreed at journal 26 Aug, 2024 Reviewers agreed at journal 26 Aug, 2024 Reviewers agreed at journal 24 Jul, 2024 Reviews received at journal 24 Jun, 2024 Reviewers agreed at journal 13 Jun, 2024 Reviewers invited by journal 13 Jun, 2024 Editor assigned by journal 07 Jun, 2024 Submission checks completed at journal 07 Jun, 2024 First submitted to journal 06 Jun, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4541315","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":316018042,"identity":"cd5fc037-b43e-4ba7-8192-88caa7667f99","order_by":0,"name":"Joanna Stanisławiak-Rudowicz","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA1ElEQVRIiWNgGAWjYLCCBAYLOTYwywCI2QkpZwNrkTBmY2CGamEmRgsDg0RiA1wpIS3y85ufPXjwRyK9T7r/4OOKAjsGc0JaDI6xmRsktknktskcZjY8Y5DMYNlMSAsbgxnQVUAtEslskg0GzAwGhwk5rI39m0QC0GFsEsnsPxsM6glrYTjGYyaRwAZCyWyMDUD1BLUYHMspkwD6xRDoMGOgw47zEPSLfPPxbZI//tjIy89IfPix4U+1nDl7AyGXoQEeAxI1MEASwCgYBaNgFIwCZAAAXK41N146/3EAAAAASUVORK5CYII=","orcid":"","institution":"Poznan University of Medical Sciences","correspondingAuthor":true,"prefix":"","firstName":"Joanna","middleName":"","lastName":"Stanisławiak-Rudowicz","suffix":""},{"id":316018043,"identity":"9fe6de64-d347-4735-ab0c-eca0b33429cc","order_by":1,"name":"Edyta Szałek","email":"","orcid":"","institution":"Poznan University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Edyta","middleName":"","lastName":"Szałek","suffix":""},{"id":316018044,"identity":"c3425df1-e30d-4117-874e-2171abeb0e4a","order_by":2,"name":"Barbara Więckowska","email":"","orcid":"","institution":"Poznan University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Barbara","middleName":"","lastName":"Więckowska","suffix":""},{"id":316018045,"identity":"f878bf0b-3f15-47f7-8a9e-0d1002c6faf2","order_by":3,"name":"Edmund Grześkowiak","email":"","orcid":"","institution":"Poznan University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Edmund","middleName":"","lastName":"Grześkowiak","suffix":""},{"id":316018046,"identity":"444e9390-bd21-446b-9c90-d8e5869560d6","order_by":4,"name":"Radosław Mądry","email":"","orcid":"","institution":"Poznań University Clinical Hospital","correspondingAuthor":false,"prefix":"","firstName":"Radosław","middleName":"","lastName":"Mądry","suffix":""}],"badges":[],"createdAt":"2024-06-06 15:12:29","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4541315/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4541315/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s43440-025-00702-z","type":"published","date":"2025-01-29T15:57:11+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":75351409,"identity":"bb360325-59b4-4e33-9c2e-bd3fe6df99a3","added_by":"auto","created_at":"2025-02-03 16:10:52","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":352502,"visible":true,"origin":"","legend":"","description":"","filename":"PharmReportsOlaparybandglycaemia03.06.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4541315/v1_covered_3c697de2-ddf9-42d1-9cc0-4755a3bd09b7.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Analysis of olaparib-induced hyperglycemia during three-month therapy with consideration of BMI of ovarian cancer patients","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"pharmacological-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"prep","sideBox":"Learn more about [Pharmacological Reports](https://link.springer.com/journal/43440)","snPcode":"43440","submissionUrl":"https://submission.springernature.com/new-submission/43440/3","title":"Pharmacological Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"olaparib, hyperglycemia, BMI, adverse effects","lastPublishedDoi":"10.21203/rs.3.rs-4541315/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4541315/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eIntroduction. \u003c/strong\u003eOlaparib is a relatively new poly(ADP-ribose) polymerase inhibitor administered to patients with ovarian cancer (OC) \u0026nbsp;\u0026nbsp;with a complete or partial response to first-line chemotherapy. One of the metabolic side effects of olaparib is disruption of glucose homeostasis, resulting in hyperglycemia\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAim.\u003c/strong\u003e The aim of the study was the retrospective analysis of olaparib-induced hyperglycemia \u0026nbsp;in OC patients with initial normoglycemia following I, II, and III cycle of olaparib treatment. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e. The study involved 32 OC patients, divided into three groups according to their BMI:\u0026nbsp; normal BMI (BMI 18.5-24.9 kg/m\u003csup\u003e2\u003c/sup\u003e; n=13), overweight (BMI 25-29.9 kg/m\u003csup\u003e2\u003c/sup\u003e; n=13), and obesity\u0026nbsp; (BMI ≥30 kg/m\u003csup\u003e2\u003c/sup\u003e; n=6). The fasting glucose (FG) levels were evaluated after I, II, and III cycle of olaparib treatment (a cycle means 28 days of olaparib treatment). The severity of observed hyperglycemia was assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults.\u003c/strong\u003e In the group with normal BMI, the increase of glycemia was statistically significant after I (p=0.0032) and II (p=0.0195) cycle of olaparib treatment, in the group with overweight – after\u0026nbsp; III (p=0.0375) cycle, and in the group with obesity – after III cycle (p=0.0152). There were no statistically significant differences in glucose levels among the groups following I (p=0.7741), II (p=0.9418) and III cycle (p=0.3431). During olaparib treatment, grade 1 hyperglycemia with impaired fasting glucose levels (5.6–6.9 mmol/l) was found in 15 \u0026nbsp;patients ( normal BMI: n=4, \u0026nbsp;overweight n=9, and \u0026nbsp;obesity n=2). Glycemia typical of diabetes (≥7.0 mmol/l) was observed in 1 obese patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions.\u003c/strong\u003e Regardless of the weight of OC patients, glycemic control in the course of olaparib treatment is indicated.\u003c/p\u003e","manuscriptTitle":"Analysis of olaparib-induced hyperglycemia during three-month therapy with consideration of BMI of ovarian cancer patients","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-06-20 20:06:55","doi":"10.21203/rs.3.rs-4541315/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-09-12T11:25:09+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-09-06T15:19:07+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"102200870817587865960926102293880016504","date":"2024-08-27T02:27:49+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"108734600448754986072155172946704887883","date":"2024-08-27T01:29:23+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"65289724361824321976484912670752199039","date":"2024-08-26T15:18:08+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"290540601787890321000873907223161780964","date":"2024-07-24T11:59:39+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-06-24T20:48:17+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"277375411072693859796194076444637076951","date":"2024-06-14T03:02:49+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-06-13T12:53:29+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-06-08T02:43:09+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-06-07T04:27:01+00:00","index":"","fulltext":""},{"type":"submitted","content":"Pharmacological Reports","date":"2024-06-06T15:11:19+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"pharmacological-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"prep","sideBox":"Learn more about [Pharmacological Reports](https://link.springer.com/journal/43440)","snPcode":"43440","submissionUrl":"https://submission.springernature.com/new-submission/43440/3","title":"Pharmacological Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"8f59836e-684b-46cd-b2b0-e750bda24673","owner":[],"postedDate":"June 20th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-02-03T16:05:09+00:00","versionOfRecord":{"articleIdentity":"rs-4541315","link":"https://doi.org/10.1007/s43440-025-00702-z","journal":{"identity":"pharmacological-reports","isVorOnly":false,"title":"Pharmacological Reports"},"publishedOn":"2025-01-29 15:57:11","publishedOnDateReadable":"January 29th, 2025"},"versionCreatedAt":"2024-06-20 20:06:55","video":"","vorDoi":"10.1007/s43440-025-00702-z","vorDoiUrl":"https://doi.org/10.1007/s43440-025-00702-z","workflowStages":[]},"version":"v1","identity":"rs-4541315","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4541315","identity":"rs-4541315","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}